CCNE2

Across TCGA pan-cancer cohorts, CCNE2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCNE2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCNE2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCNE2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

HNSC, LIHC, and CESC are the cancer types where CCNE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.169	0.710	.008	24	view →
LIHC	DFS	Median	All	0.044	0.543	<.001	12	view →
CESC	OS	Median	All	0.261	0.798	.020	6	view →
UCEC	DFS	Median	All	1.000	0.623	.029	4	view →
SKCM	DFS	Median	II,III,IV	1.000	0.249	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCNE2–HNSC (OS)

Open the HNSC breakdown →